Literature DB >> 11971872

Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice.

Zhao-Xue Yu1, Shi-Hua Li, Huu-Phuc Nguyen, Xiao-Jiang Li.   

Abstract

A pathological hallmark of polyglutamine diseases is the presence of inclusions or aggregates of the expanded polyglutamine protein. Polyglutamine inclusions are present in the neuronal nucleus in a number of inherited neurodegenerative disorders, including Huntington disease (HD). Recent studies suggest that polyglutamine inclusions may sequester polyglutamine-containing transcription factors and deplete their concentration in the nucleus, leading to altered gene expression. To test this hypothesis, we examined the expression and localization of the polyglutamine-containing or glutamine-rich transcription factors TBP, CBP and Sp1 in HD mouse models. All three transcription factors were diffusely distributed in the nucleus, despite the presence of abundant intranuclear inclusions. There were no differences in the nuclear staining of these transcription factors between HD and wild-type mouse brains. Although some CBP staining appeared as dots in the selective brain regions (e.g. hypothalamus and amygdala), double labeling showed that most CBP was not co-localized with huntingtin nuclear inclusions. Electron microscopy confirmed that CBP was diffusely distributed in the nucleus. Western blots showed that these transcription factors were not trapped in huntingtin inclusions. In the striatum of HD mice, which suffers a significant reduction in the expression of a number of genes, mutant huntingtin was present in both an aggregated and a diffuse form. These findings suggest that altered gene expression may result from the interactions of soluble mutant huntingtin with nuclear transcription factors, rather than from the depletion of transcription factors by nuclear inclusions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11971872     DOI: 10.1093/hmg/11.8.905

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  32 in total

Review 1.  Neuronal degeneration and mitochondrial dysfunction.

Authors:  Eric A Schon; Giovanni Manfredi
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

2.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

3.  Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.

Authors:  Paula A Desplats; James R Lambert; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2008-05-22       Impact factor: 5.996

4.  Mutant huntingtin fragment selectively suppresses Brn-2 POU domain transcription factor to mediate hypothalamic cell dysfunction.

Authors:  Tomoyuki Yamanaka; Asako Tosaki; Haruko Miyazaki; Masaru Kurosawa; Yoshiaki Furukawa; Mizuki Yamada; Nobuyuki Nukina
Journal:  Hum Mol Genet       Date:  2010-02-25       Impact factor: 6.150

Review 5.  Shaping the role of mitochondria in the pathogenesis of Huntington's disease.

Authors:  Veronica Costa; Luca Scorrano
Journal:  EMBO J       Date:  2012-03-23       Impact factor: 11.598

Review 6.  Histone methylation in the nervous system: functions and dysfunctions.

Authors:  Céline Pattaroni; Claire Jacob
Journal:  Mol Neurobiol       Date:  2012-11-17       Impact factor: 5.590

7.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

8.  Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor.

Authors:  Tomoyuki Yamanaka; Haruko Miyazaki; Fumitaka Oyama; Masaru Kurosawa; Chika Washizu; Hiroshi Doi; Nobuyuki Nukina
Journal:  EMBO J       Date:  2008-02-21       Impact factor: 11.598

9.  Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors.

Authors:  M Futter; H Diekmann; E Schoenmakers; O Sadiq; K Chatterjee; D C Rubinsztein
Journal:  J Med Genet       Date:  2009-05-17       Impact factor: 6.318

10.  HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease.

Authors:  Joanna L Howarth; Colin P J Glover; James B Uney
Journal:  J Neurochem       Date:  2009-02       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.